Impact of Anti-Thymocyte Globulin During Immunosuppression Induction in Patients with Hepatitis C After Liver Transplantation
- 28 May 2014
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 59 (11) , 2804-2812
Abstract
Induction immunosuppression with anti-thymocyte globulin (ATG) provides potential benefits after liver transplantation (LT). However, its use in patients with LT and hepatitis C (HCV) is controversial.Keywords
This publication has 43 references indexed in Scilit:
- Incidence and Risk Factors of Hepatocellular Carcinoma Recurrence After Liver Transplantation in the MELD EraDigestive Diseases and Sciences, 2011
- Chronic Hepatitis C InfectionNew England Journal of Medicine, 2011
- Anti-thymocyte Globulin for the Treatment of Acute Cellular Rejection Following Liver TransplantationDigestive Diseases and Sciences, 2010
- The Influence of Induction Therapy on Graft and Patient Survival in Patients with and without Hepatitis C after Liver TransplantationAmerican Journal of Transplantation, 2010
- Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: A five-year randomized prospective studyLiver Transplantation, 2009
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Outcomes in hepatitis C virus–infected recipients of living donor vs. deceased donor liver transplantationLiver Transplantation, 2006
- Minimization of immunosuppression with thymoglobuline pre-treatment and HCV recurrence in liver transplantationClinical Transplantation, 2005
- Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipientsLiver Transplantation, 2004
- Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy1Transplantation, 2003